Paraproteinemias D010265

Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Blood Protein Disorders » Paraproteinemias

Diseases [C] » Immune System Diseases [C20] » Immunoproliferative Disorders » Paraproteinemias

Description

A group of related diseases characterized by an unbalanced or disproportionate proliferation of immunoglobulin-producing cells, usually from a single clone. These cells frequently secrete a structurally homogeneous immunoglobulin (M-component) and/or an abnormal immunoglobulin.   MeSH

Subtype Terms (8)

Cryoglobulinemia
7 approved drugs

Heavy Chain Disease
 

Immunoglobulin Light-chain Amyloidosis
54 drugs (40 approved, 14 experimental)

Monoclonal Gammopathy of Undetermined Significance
18 drugs (12 approved, 6 experimental)

Multiple Myeloma
860 drugs (291 approved, 569 experimental)

POEMS Syndrome
8 drugs (6 approved, 2 experimental)

Smoldering Multiple Myeloma
31 drugs (19 approved, 12 experimental)

Waldenstrom Macroglobulinemia
171 drugs (92 approved, 79 experimental)


Phase 4 Indicated Drugs (1)

Phase 3 Indicated Drugs (1)

Phase 1 Indicated Drugs (1)

Other Experimental Indicated Drugs (2)


Organization Involved with Phase 4 Indications (1)

Organization Involved with Other Experimental Indications (1)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.